ERBB2 and cancer: However, its capacity for late recurrences, even several years post initial diagnosis and treatment, underscores the necessity for long-term surveillance in clinical management.2 HER2-positive breast cancer, on the other hand, denotes the overexpression of the human epidermal growth factor receptor 2, a protein that promotes the growth of cancer cells.